RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q4 2023

Top Holdings64 positions

Checking export access…
Activity:

ROCKET PHARMACEUTICALS INC

17.7M$530.1M8.3%$18.77+59.66%
20 qtrssince 2019-Q1
Unchanged
0
IMCRIMCR
ADR

IMMUNOCORE HOLDINGS PLC

6.1M$416.5M6.5%$43.70+56.34%
12 qtrssince 2021-Q1
Unchanged
0
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

6.8M$397.7M6.2%——
20 qtrssince 2019-Q1
Unchanged
0

AXSOME THERAPEUTICS INC

4.5M$357.3M5.6%$61.42+29.59%
20 qtrssince 2019-Q1
Unchanged
0

ACADIA PHARMACEUTICALS INC

11.3M$352.3M5.5%$18.32+70.95%
7 qtrssince 2022-Q2
Decreased
0

ULTRAGENYX PHARMACEUTICAL INC

6.9M$329.3M5.1%$53.17-10.06%
9 qtrssince 2021-Q4
Increased
75

ALNYLAM PHARMACEUTICALS INC

1.6M$314M4.9%$94.58+145.11%
20 qtrssince 2019-Q1
Decreased
0
ARGXARGX
ADR

ARGENX SE

667,195$253.8M4.0%$348.48+9.17%
20 qtrssince 2019-Q1
Increased
72

BRUKER CORP

3.3M$245.7M3.8%$72.62+0.38%
4 qtrssince 2023-Q1
Decreased
0

CYTOKINETICS INC

2.5M$210.8M3.3%$27.00+209.20%
14 qtrssince 2020-Q3
Decreased
0

PTC THERAPEUTICS INC

7.4M$204.6M3.2%$43.39-36.48%
20 qtrssince 2019-Q1
Increased
58

MADRIGAL PHARMACEUTICALS INC

815,191$188.6M2.9%$222.07+4.19%
3 qtrssince 2023-Q2
Increased
84

ARVINAS INC

4.2M$173.4M2.7%$41.160.00%
1 qtr
New
79
MASIMASIDelisted

MASIMO CORP

1.5M$171.4M2.7%$174.28-32.75%
20 qtrssince 2019-Q1
Decreased
0

PENUMBRA INC

662,664$166.7M2.6%$262.94-4.33%
10 qtrssince 2021-Q3
Decreased
0

NATERA INC

2.6M$162.4M2.5%$42.80+46.37%
18 qtrssince 2019-Q3
Decreased
0

CELLDEX THERAPEUTICS INC

3.5M$137.4M2.1%$16.73+150.93%
15 qtrssince 2020-Q2
Unchanged
0

PROTAGONIST THERAPEUTICS INC

5.3M$121.9M1.9%$22.34+2.66%
18 qtrssince 2019-Q3
Decreased
0
CRGXCRGXDelisted

CARGO THERAPEUTICS INC

5.2M$119.8M1.9%——
1 qtr
New
69

VERICEL CORP

3.2M$114.4M1.8%$17.86+99.44%
20 qtrssince 2019-Q1
Decreased
0
$6.4B
AUM
64
Positions
Q4 2023
Filing
HI score · 2.0/5
Quarterly 13F Value Change
+12%Q3'22$4.3B+13%Q4'22$4.9B-2%Q1'23$4.8B+9%Q2'23$5.3B-10%Q3'23$4.7B+35%Q4'23$6.4B
Activity profile
$ moved · Q4'23
New33%Increased26%Decreased32%Exited9%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.3 years
<1Q16%1-4Q20%1-2Y2%2Y+63%

RTW INVESTMENTS, LP manages $6.4B across 64 positions as of Q4 2023. Top holdings: RCKT (8.3%), IMCR (6.5%), MRTX (6.2%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2/5.0.

Q4 2023 Summary

Active quarter - 14 new positions, 17 exits, 12 increased. Top move: MDGL (INCREASED, conviction 84). Portfolio: $6.4B across 64 positions.

Top holdings by portfolio weight

Total AUM$6B
RCKT8.28%
IMCR6.51%
MRTX6.21%
AXSM5.58%
ACAD5.50%
RARE5.14%
ALNY4.91%
ARGX3.96%
BRKR3.84%
CYTK3.29%
Other3.20%

Portfolio allocation by GICS sector

Sectors2
Healthcare85.03%
Unknown14.97%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L48
Conviction44
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRADNET INC
Q4 2024 → Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 → Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 → Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used